NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free ADMA Stock Alerts $8.81 +1.88 (+27.13%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$7.96▼$9.0250-Day Range$5.72▼$8.8152-Week Range$3.06▼$9.02Volume11.70 million shsAverage Volume2.20 million shsMarket Capitalization$2.01 billionP/E RatioN/ADividend YieldN/APrice Target$10.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ADMA Biologics alerts: Email Address ADMA Biologics MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside19.2% Upside$10.50 Price TargetShort InterestHealthy3.82% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 34 Articles This WeekInsider TradingSelling Shares$3.93 M Sold Last QuarterProj. Earnings Growth61.29%From $0.31 to $0.50 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.88 out of 5 starsMedical Sector413th out of 925 stocksBiological Products, Except Diagnostic Industry58th out of 154 stocks 2.6 Analyst's Opinion Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageADMA Biologics has only been the subject of 4 research reports in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.82% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADMA Biologics has recently increased by 7.52%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADMA. Previous Next 3.2 News and Social Media Coverage News SentimentADMA Biologics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 34 news articles for ADMA Biologics this week, compared to 4 articles on an average week.Search InterestOnly 23 people have searched for ADMA on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat Follows22 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 22% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,927,169.00 in company stock.Percentage Held by InsidersOnly 3.70% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ADMA Biologics are expected to grow by 61.29% in the coming year, from $0.31 to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is -440.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is -440.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 14.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ADMA Biologics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About ADMA Biologics Stock (NASDAQ:ADMA)ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Read More ADMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADMA Stock News HeadlinesMay 12, 2024 | seekingalpha.comGiving ADMA Biologics A Well-Deserved 'Booyah'May 12, 2024 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) PT Raised to $12.00 at MizuhoMay 12, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” May 12, 2024 | americanbankingnews.comHC Wainwright Increases ADMA Biologics (NASDAQ:ADMA) Price Target to $10.00May 12, 2024 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) PT Raised to $10.00May 12, 2024 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) PT Raised to $10.00 at Cantor FitzgeraldMay 11, 2024 | cnn.comADMA Biologics, Inc.May 11, 2024 | finance.yahoo.comADMA Biologics First Quarter 2024 Earnings: Beats ExpectationsMay 12, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” May 11, 2024 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) Shares Gap Up on Earnings BeatMay 10, 2024 | markets.businessinsider.comStrong Financial Performance and Growth Prospects Affirm Buy Rating for ADMA BiologicsMay 10, 2024 | marketwatch.comADMA Biologics Shares Rise 23% After 1Q Earnings Beat EstimatesMay 10, 2024 | msn.comADMA Biologics hits 52-week high on Q1 beat, guidance raiseMay 10, 2024 | finance.yahoo.comADMA Biologics Inc (ADMA) Surpasses Analyst Revenue and Earnings Forecasts in Q1 2024May 10, 2024 | finance.yahoo.comADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2024 Earnings Call TranscriptMay 10, 2024 | msn.comADMA Biologics Analysts Increase Their Forecasts After Upbeat ResultsMay 9, 2024 | chron.comAdma Biologics: Q1 Earnings SnapshotMay 9, 2024 | markets.businessinsider.comADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | globenewswire.comADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | markets.businessinsider.comADMA Biologics is about to announce its earnings — here's what to expectMay 8, 2024 | americanbankingnews.comADMA Biologics (ADMA) Scheduled to Post Earnings on ThursdayMay 6, 2024 | msn.comChart of the Day: ADMA Biologics - Hitting New HighsMay 5, 2024 | americanbankingnews.comADMA Biologics (NASDAQ:ADMA) Reaches New 1-Year High at $6.80May 2, 2024 | globenewswire.comADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024April 28, 2024 | seekingalpha.com3 'Buy-Rated' Biotech Stocks Under $10April 25, 2024 | finance.yahoo.comAdma Biologics (ADMA) Stock Moves -0.31%: What You Should KnowApril 16, 2024 | morningstar.comADMA Biologics IncSee More Headlines Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/12/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADMA CUSIPN/A CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees624Year FoundedN/APrice Target and Rating Average Stock Price Target$10.50 High Stock Price Target$12.00 Low Stock Price Target$10.00 Potential Upside/Downside+19.2%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E Ratio28.42 P/E GrowthN/ANet Income$-28,240,000.00 Net Margins-1.29% Pretax Margin-10.94% Return on Equity17.51% Return on Assets7.43% Debt Debt-to-Equity Ratio1.04 Current Ratio5.16 Quick Ratio1.69 Sales & Book Value Annual Sales$258.21 million Price / Sales7.79 Cash Flow$0.05 per share Price / Cash Flow173.36 Book Value$0.60 per share Price / Book14.68Miscellaneous Outstanding Shares228,220,000Free Float219,776,000Market Cap$2.01 billion OptionableOptionable Beta0.43 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Adam S. Grossman (Age 47)Co-Founder, President, CEO & Director Comp: $1.52MDr. Jerrold B. Grossman D.P.S. (Age 76)Ph.D., Co-Founder & Vice Chairman of the Board Comp: $80kMr. Brian Lenz CPA (Age 52)Executive VP, CFO & GM of ADMA BioCenters Comp: $1.08MMs. Kaitlin Kestenberg (Age 37)COO & Senior VP of Compliance Mr. Drew PantelloVice President of Marketing & Corporate DevelopmentMs. Cindy PetersenExecutive Director of Human ResourcesMr. Skyler BloomSenior Director of Business Development & Corporate StrategyMore ExecutivesKey CompetitorsNeumora TherapeuticsNASDAQ:NMRATarsus PharmaceuticalsNASDAQ:TARS4D Molecular TherapeuticsNASDAQ:FDMTInhibrxNASDAQ:INBXFusion PharmaceuticalsNASDAQ:FUSNView All CompetitorsInsiders & InstitutionsHillsdale Investment Management Inc.Bought 628,400 shares on 5/11/2024Ownership: 0.276%Vanguard Group Inc.Sold 202,481 shares on 5/10/2024Ownership: 5.560%Russell Investments Group Ltd.Bought 556,175 shares on 5/8/2024Ownership: 0.512%Inspire Investing LLCBought 105,256 shares on 5/8/2024Ownership: 0.083%ProShare Advisors LLCBought 4,570 shares on 5/8/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions ADMA Stock Analysis - Frequently Asked Questions Should I buy or sell ADMA Biologics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADMA shares. View ADMA analyst ratings or view top-rated stocks. What is ADMA Biologics' stock price target for 2024? 4 brokers have issued 1 year price objectives for ADMA Biologics' shares. Their ADMA share price targets range from $10.00 to $12.00. On average, they predict the company's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 19.2% from the stock's current price. View analysts price targets for ADMA or view top-rated stocks among Wall Street analysts. How have ADMA shares performed in 2024? ADMA Biologics' stock was trading at $4.52 at the beginning of the year. Since then, ADMA shares have increased by 94.9% and is now trading at $8.81. View the best growth stocks for 2024 here. When is ADMA Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our ADMA earnings forecast. How were ADMA Biologics' earnings last quarter? ADMA Biologics, Inc. (NASDAQ:ADMA) issued its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.05 by $0.03. The biotechnology company earned $81.90 million during the quarter, compared to analysts' expectations of $77.28 million. ADMA Biologics had a positive trailing twelve-month return on equity of 17.51% and a negative net margin of 1.29%. The business's revenue for the quarter was up 43.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.03) EPS. What ETFs hold ADMA Biologics' stock? ETFs with the largest weight of ADMA Biologics (NASDAQ:ADMA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Inspire Fidelis Multi Factor ETF (FDLS), Invesco DWA SmallCap Momentum ETF (DWAS), First Trust Small Cap Growth AlphaDEX Fund (FYC) and iShares Micro-Cap ETF (IWC).First Trust Small Cap Core AlphaDEX Fund (FYX). What guidance has ADMA Biologics issued on next quarter's earnings? ADMA Biologics updated its FY 2025 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $410.0 million-, compared to the consensus revenue estimate of $389.9 million. What is Adam S. Grossman's approval rating as ADMA Biologics' CEO? 9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT). Who are ADMA Biologics' major shareholders? ADMA Biologics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.56%), Assenagon Asset Management S.A. (1.47%), Mesirow Institutional Investment Management Inc. (1.14%), Rice Hall James & Associates LLC (0.53%), Russell Investments Group Ltd. (0.51%) and Peregrine Capital Management LLC (0.36%). Insiders that own company stock include Adam S Grossman, Brian Lenz, Bryant Fong, Jerrold B Grossman, Perceptive Advisors Llc, Steve Elms and Young Kwon. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADMA) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCollapse of the Petrodollar Colonial MetalsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
